Transparency Market Research, in its latest report titled “Antibacterial Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 – 2023”, reveals that the global antibacterial drugs market is forecast to witness a rather slow growth from 2015 to 2023 owing to patent expiries of blockbuster drugs. Even though the market will register a meager CAGR of 1.30% during the forecast period, the value is anticipated to decline from US$43.9 bn in 2014 to US$38.9 bn in 2023.
High prevalence of infectious diseases, government support and increased research and development activities, and product differentiation through various methods drive the antibacterial drugs market. However, rise in drug-resistant species, launch of generics, and upcoming patent expirations are anticipated to restrict the growth of the global market through 2023.The report offers a pipeline analysis of some of the key antibacterial drugs such as Zempia, Actoxumab/Aezlotoxumab, RHB-105, SYM-1219, Ozenoxacin, SPL7013, Cadazolid, Arikace, Surotomycin, Eravacycline, Carbavance, Delamanid, Omadacycline, Solithromycin, Ciprofloxacin/Fluocinolone Acetonide, Delafloxacin, and Plazomycin.
Based on drug class, the antibacterial drugs market is categorized into B-lactams, sulfonamides, macrolides, aminoglycosides, tetracyclines, quinolones/fluoroquinolones, phenicols, and miscellaneous antibacterials. Accounting for a share of 57.70% in the overall antibacterial drugs market in 2014, B-lactams dominated the scene. However, this drug class is anticipated to witness a drop in market share by 2023. The miscellaneous antibacterials category, on the other hand, is projected to develop at the highest growth rate from 2015 to 2023.
Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1567
Geographically, the global antibacterial drugs market is segmented into North America, Asia Pacific, Latin America, Europe, and Rest of the World. Asia Pacific presently dominates the overall market and is also projected to witness the fastest growth over the duration of the forecast period. The Asia Pacific antibacterial drugs market is fueled by rising incidences of bacterial infections such as tuberculosis and MRSA, presence of large number of manufacturers of active pharmaceutical ingredient and generic drugs, rising purchasing power of the domestic population, expanding geriatric population, and developing healthcare infrastructure.
North America, followed by Europe, is the second largest regional market for antibacterial drugs in terms of revenue. These regions are anticipated to witness slow growth over the next seven years owing to stringent regulatory requirements, shortened product lifecycle, and generic infiltration.
The research report identifies and assesses the performance of the key players operating in the global antibacterial drugs market. These players are profiled based on attributes such as company and financial overview, business strategies, product portfolio, and recent developments. The companies featured in the antibacterial drugs market report are GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc., Pfizer, Inc., Sanofi, Johnson & Johnson, Bristol-Myers Squibb Company, AstraZeneca plc, Allergan plc (Actavis Plc), Bayer AG, and Eli Lilly and Company.
Transparency Market Research
90 State Street,
NY – 12207
USA – Canada Toll Free 866-552-3453